NexImmune
- Founded: 2011
- Location: Gaithersburg, MD
- Employee range: 11 - 50
- Clinical stage: Clin1/Clin2
- Therapy area: AML/MDS
- Drug types: ONC, IMM, INF
- Lead product: NEXI-001
- Product link: https://neximmune.com/our-pipeline/
- Funding: $126.5M IPO Feb 2021; $23M A Jan 2018
neximmune.com linkedin.com job board
Short description:
Artificially engineered antigen-presenting cells
Drug notes:
Also Clin0 multiple cancers; NEXI-002 Clin1 (paused Aug 2022) multiple myeloma, Clin0 autoimmune diseases; NEXI-003 Clin0/Clin1 HPV cancers, Clin0 infectious diseases; NEXI-004 Clin0 EBV diseases
Long description:
NexImmune is developing unique T cell immunotherapies for cancer, autoimmune and infectious diseases. Using naturally-occurring biology, NexImmune is orchestrating a targeted cell-mediated immune response across a broad range of diseases through the use of their Artificial Immune Modulation (AIM) technology. AIM nanoparticles act as synthetic immune cells that deliver immune-specific signals to targeted T cells, directing activation or suppression, depending on the indication. The modular approach means the technology can be applied across multiple therapeutic areas, both ex vivo or as injectable products.
Jobs:
© 2024 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com